CLTC: A Potential Drug Target Or Biomarker (G1213)

Target Name: CLTC

NCBI ID: G1213

CLTC

CLTC: A Potential Drug Target Or Biomarker

CLTC, or clathrin heavy polypeptide-like 2, is a protein that is expressed in various tissues throughout the body. It is a member of the clathrin gene family, which is known for the formation of cytoplasmic granules that are involved in various cellular processes. CLTC has been shown to play a role in the regulation of cell signaling pathways, and is potential drug target or biomarker.

CLTC is a 21-kDa protein that is expressed in a variety of tissues, including muscle, heart, brain, and liver. It is characterized by a unique N-terminus that consists of a 21 amino acid residue, as well as a C-terminus that is composed of a single amino acid residue. The unique N-terminus of CLTC is thought to be involved in its ability to interact with other proteins, as well as its ability to form inclusion bodies in the cytoplasm.

CLTC is involved in the regulation of a number of cellular signaling pathways, including the TGF-β pathway and the Wnt pathway. TGF-β is a cytokine that is involved in the regulation of cell growth, differentiation, and inflammation. The TGF-β pathway is a complex signaling pathway that is involved in the regulation of cell signaling pathways, including the regulation of cell growth, differentiation, and inflammation. CLTC is known to be involved in the regulation of TGF-β signaling by forming inclusion bodies in the cytoplasm.

CLTC is also involved in the regulation of the Wnt pathway, which is a signaling pathway that is involved in the regulation of cell growth, differentiation, and development. The Wnt pathway is thought to be involved in the regulation of cell signaling pathways, including the regulation of cell growth, differentiation, and development. CLTC is known to be involved in the regulation of Wnt signaling by forming inclusion bodies in the cytoplasm.

CLTC is also involved in the regulation of the cell signaling pathway known as the Runx/TGF-β pathway. The Runx/TGF-β pathway is a signaling pathway that is involved in the regulation of cell signaling pathways, including the regulation of cell growth, differentiation, and inflammation. CLTC is known to be involved in the regulation of Runx/TGF-β signaling by forming inclusion bodies in the cytoplasm.

In addition to its involvement in the regulation of cellular signaling pathways, CLTC is also potential drug target or biomarker. CLTC has been shown to play a role in the regulation of cell signaling pathways, and is therefore a potential drug target or biomarker. Additionally, the unique N-terminus of CLTC is thought to be involved in its ability to interact with other proteins, which may make it a potential protein-protein interaction target. Further research is needed to fully understand the role of CLTC in the regulation of cellular signaling pathways and its potential as a drug target or biomarker.

Protein Name: Clathrin Heavy Chain

Functions: Clathrin is the major protein of the polyhedral coat of coated pits and vesicles. Two different adapter protein complexes link the clathrin lattice either to the plasma membrane or to the trans-Golgi network. Acts as component of the TACC3/ch-TOG/clathrin complex proposed to contribute to stabilization of kinetochore fibers of the mitotic spindle by acting as inter-microtubule bridge (PubMed:15858577, PubMed:16968737, PubMed:21297582). The TACC3/ch-TOG/clathrin complex is required for the maintenance of kinetochore fiber tension (PubMed:23532825). Plays a role in early autophagosome formation (PubMed:20639872)

The "CLTC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLTC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets